IFNA1 and neoplasm: Ruxolitinib, a JAK/STAT inhibitor, has also been employed to enhance viral replication by inhibiting interferon responses in IFN-competent tumor cells, allowing for improved OV propagation while mitigating the risk of excessive cytokine release or rapid tumor lysis syndrome (122).